Amprion specializes in the detection of misfolded alpha-synuclein proteins, which are associated with various neurodegenerative disorders, including Alzheimer's disease, Lewy body dementia, and atypical Parkinson's disease. The company has developed the SAAmplify-αSYN Test, a validated seed amplification assay that enhances diagnostic accuracy for these conditions. This innovative technology allows for early diagnosis, stratification, and management of patients, thereby supporting precision medicine in the field of neurology. The test is particularly beneficial in differentiating between similar disorders, such as multiple system atrophy and Parkinson's disease, and in identifying minimal cognitive impairment with Lewy bodies.

Amprion's research is grounded in decades of scientific inquiry into prion detection and misfolded protein dynamics. The company has published numerous studies demonstrating the sensitivity and specificity of their assays, which have shown potential in unmasking pathology and facilitating biologically-based therapeutic development. Their work not only aids in the accurate diagnosis of neurodegenerative diseases but also contributes to a deeper understanding of the underlying mechanisms of these conditions, paving the way for future advancements in treatment and care.

United States

Amprion pioneers Testing for diseases associated with mis-folded proteins.  Our flagship product - SYNTap is the assay used by the Michael J Fox Foundations Parkinson's Progression and Markers Initiative (PPMI) to define PD and DLB and its stages. 

Early diagnosis of synucleinopathies can help guide management, treatment and prognostic discussions.  

https://www.ampriondx.com

Amprion

Company Details